assessed the safety and preliminary efficacy of TIL therapy in combination with nivolumab in the nivolumab (a PD-1 inhibitor) monotherapy of advanced-stage NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.